The CSL Limited (ASX: CSL) share price is having a decent year so far.
Since the start of 2023, the biotherapeutics giantâs shares have risen almost 5% to close at $301.27 on Monday.
This compares favourably to the ASX 200 index and its 3.4% gain.
The big question now, though, is can the CSL share price keep rising?
In order to answer this question, letâs take a look at what brokers are saying about the companyâs shares.
Can the CSL share price keep rising?
Well, I have good news for you. All the major brokers believe the CSL share price has room to climb from current levels.
Hereâs a summary in alphabetical order:
The team at Citi currently has a buy rating and $350 price target on the companyâs shares. This implies potential upside of over 16% for investors over the next 12 months. Incidentally, this is the highest price target that I have seen.
Goldman Sachs is sitting on the fence at the moment with its neutral rating and $314.00 price target. This suggests the CSL share price could rise a little over 4% from here. Not great, but a gain is a gain.
Moving on, Macquarie is a fan and currently has an outperform rating and $344.00 price target on its shares. If it reached this level, it would mean a gain of just over 14%.
Analysts at Morgan Stanley are also positive on CSL. They currently have an overweight rating and $339.00 price target, which implies potential upside of 12.5% for investors.
Finally, Morgans is another broker that is bullish on the company. It currently has an add rating and $337.92 price target on its shares. This would mean a 12% gain if the CSL share price climbed to this level.
All in all, it seems that now is a good time to be a shareholder of this biotherapeutics leader if brokers are on the money with their recommendations.
The post What are brokers saying about the CSL share price in May? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of April 3 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Should I buy up CSL shares right now while they’re under $300?
- Morgans names the best ASX 200 stocks to buy in May
- Can the CSL share price crack a new, all-time high in 2023?
- These ASX 200 shares could be top options for your retirement portfolio: experts
- ‘Under the radar success’: 3 quality ASX 200 growth shares to buy right now
Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/SMOCsJU
Stock Pick 